Debiopharm

This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.

Merck and Roche team up for hepatitis C studies

Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's

Latest news

More Eloxatin settlements for sanofi-aventis

Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.
Sanofi-aventis settles Eloxatin lawsuits

medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.
Novartis gain rights to hepatitis C drug

The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).
HCV hope on the horizon

The ciclosporin analogue DEBIO 025 (Debiopharm) is a first-in-class cyclophilin inhibitor that has been generally well tolerated in clinical trials to date and may have potential as an addition
Pandemic preparedness

Micombi (Nippon Boehringer Ingelheim, Astellas Pharma). Hypertension. Japan. Triptorelin. Salvacyl (Debiopharm).

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals during January 2013

Debiopharm. Chugai. Licence. Exclusive worldwide licence to FF 284 in oncology.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Vice President: Competitive Salary Offered

Consultant: competitive salary

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Account Manager– Medical Communications: (Negotiable - depending on experience)

Subscribe to our email news alerts

PMHub

Add my company

Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat: A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product: In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team: Enhanced expertise to deliver impactful internal training programmes for healthcare clients...